Altesa BioSciences Gets FDA Clearance for Vapendavir to Treat Rhinovirus

Altesa BioSciences has received clearance from the U.S. Food and Drug Administration (FDA) for its vapendavir treatment for rhinovirus infections in individuals with chronic obstructive pulmonary disease (COPD).

Rhinovirus, the most common cause of the common cold, is a leading contributor to worsening lung function in people with COPD. Viral infections are a significant cause of acute health complications in this patient group.

COPD affects over 16.4 million people in the United States, accounting for 6.6% of the adult population. The condition remains a major cause of mortality both in the U.S. and worldwide.

Vapendavir is an oral broad-spectrum antiviral treatment designed to prevent the virus from entering human cells and replicating. It has demonstrated strong activity against 97% of rhinoviruses and other respiratory enteroviruses. 

This approval allows the company to begin clinical trials in the United States.    

The development of vapendavir is informed by experience in large-scale testing and diagnostics. Altesa aims to apply lessons learned from previous public health initiatives to improve treatment accessibility and effectiveness. 

The company is also exploring the drug’s potential to benefit other patient groups, including individuals with asthma, other lung conditions, cancer, and children affected by rhinovirus infections, which are a leading cause of hospitalisation in paediatric patients.

By targeting the underlying cause of disease, the company seeks to offer an alternative to long-term, immune-modifying treatments that contribute to high healthcare costs.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!